CYP51A1P1: A Potential Drug Target and Biomarker (G83528)

Target Name: CYP51A1P1

NCBI ID: G83528

CYP51A1P1

Other Name(s): Cytochrome P450 family 51 subfamily A member 1 pseudogene 1 | cytochrome P450 family 51 subfamily A member 1 pseudogene 1 | CYP51P1

CYP51A1P1: A Potential Drug Target and Biomarker

CYP51A1P1, also known as CYP51A1P1 pseudogene 1, is a member of the Cytochrome P450 (CYP) family 51 subfamily A gene. The CYP51A1P1 gene is located on chromosome 19 at position 386.2, and it encodes for a protein known as CYP51A1P1.

CYP51A1P1 is a 14-kDa protein that is expressed in various tissues and organs, including the liver, heart, kidneys, and intestines. It is primarily localized to the cytoplasm of cells and is involved in the metabolism of a wide variety of drugs and other compounds.

One of the primary functions of CYP51A1P1 is its role in drug metabolism. It is a potent enzyme that is involved in the metabolism of many drugs, including statins, antidepressants, and benzodiazepines. CYP51A1P1 is also involved in the metabolism of other drugs that are used to treat various diseases, such as diabetes, cancer, and neurological disorders.

In addition to its role in drug metabolism, CYP51A1P1 is also a potential biomarker for several diseases. For example, individuals who have genetic variations in the CYP51A1P1 gene have been shown to have altered levels of certain metabolites in their bloodstream. These changes in metabolites can be used to diagnose and monitor certain diseases, such as cardiovascular disease and cancer.

Another potential function of CYP51A1P1 is its role in cancer progression. Several studies have shown that individuals with certain genetic variations in the CYP51A1P1 gene are more likely to develop certain types of cancer, such as breast cancer and colorectal cancer. These genetic variations can also affect the sensitivity of cancer cells to certain treatments, which can have a significant impact on treatment outcomes.

Despite its potential as a drug target and biomarker, CYP51A1P1 is not yet widely studied. There are only a few studies that have investigated the role of CYP51A1P1 in drug metabolism and cancer progression. However, these studies have identified several potential targets for future research, including the development of new drugs that can specifically target CYP51A1P1.

In conclusion, CYP51A1P1 is a gene that encodes for a protein that is involved in the metabolism of a wide variety of drugs and other compounds. It is also a potential biomarker for several diseases, including drug metabolism and cancer progression. Further research is needed to fully understand the role of CYP51A1P1 in these areas and to develop new treatments that can specifically target this protein.

Protein Name: Cytochrome P450 Family 51 Subfamily A Member 1 Pseudogene 1

The "CYP51A1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP51A1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets